Epidermal growth factor receptor inhibitor therapy-associated erythema dyschromicum perstans-like eruption: a case series

Epidermal growth factor receptor inhibitor therapy-associated erythema dyschromicum perstans-like eruption: a case series.

• K J Ransohoff
• S B Pugliese
• L C Zaba
• K E Rieger
• B Y Kwong

抄録

上皮成長因子受容体阻害薬（EGFRi）は、さまざまな固形悪性腫瘍に使用されている。皮膚有害事象は一般的であり、最大90％の患者に見られる丘疹性膿疱性発疹（Papulopustular eruptions：PPE）、皮膚乾燥症、粘膜炎、爪周囲炎、多毛症、放射線皮膚炎などが含まれる。ここでは、EGFRisの投与中にEDP様発疹を発症した8名の患者の新規症例シリーズを紹介する。

Epidermal growth factor receptor inhibitors (EGFRi) are used for a variety of solid malignancies. Cutaneous adverse events are common, and include papulopustular eruptions (PPEs) in up to 90% of patients, xerosis, mucositis, paronychia, hypertrichosis, and enhanced radiation dermatitis. Here, we present a novel case series of eight patients who developed erythema dyschromicum perstans (EDP)-like eruptions while receiving EGFRis.

This article is protected by copyright. All rights reserved.